{"id":"low-dose-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Low dose chemotherapy regimens deliver sub-standard doses of conventional chemotherapeutic drugs, either as monotherapy or in combination, to achieve anti-tumor effects with reduced hematologic and non-hematologic toxicity. This approach is particularly relevant in elderly patients, those with comorbidities, or in metronomic dosing schedules where continuous low-level exposure may enhance anti-angiogenic effects and immune modulation.","oneSentence":"Low dose chemotherapy uses reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing systemic toxicity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:33.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (specific indications dependent on Phase 3 trial design)"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT07497386","phase":"PHASE2","title":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-04","conditions":"Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer","enrollment":150},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT02905591","phase":"PHASE2","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph J. Cullen, MD, FACS","startDate":"2018-11-16","conditions":"Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer","enrollment":43},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07484932","phase":"NA","title":"TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-05-01","conditions":"Cancer (Solid Tumors), Geriatric Oncology","enrollment":400},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05941741","phase":"PHASE3","title":"IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-10","conditions":"Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy","enrollment":380},{"nctId":"NCT07015944","phase":"NA","title":"Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan","status":"RECRUITING","sponsor":"Pakistan Institute of Living and Learning","startDate":"2025-06-13","conditions":"Major Depressive Disorder (MDD), Breast Cancer Survivor","enrollment":26376},{"nctId":"NCT05990738","phase":"PHASE1","title":"DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-14","conditions":"Small Cell Lung Carcinoma (SCLC)","enrollment":69},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT07372924","phase":"PHASE2","title":"A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02-24","conditions":"Abirritation in the ICU","enrollment":120},{"nctId":"NCT04579523","phase":"PHASE1","title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT03196427","phase":"PHASE2","title":"Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-07-30","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":59},{"nctId":"NCT03875716","phase":"NA","title":"Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-05-20","conditions":"Head and Neck Cancer","enrollment":111},{"nctId":"NCT07108283","phase":"PHASE2","title":"A Study of Zasocitinib in Adults With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-03","conditions":"Nonsegmental Vitiligo","enrollment":200},{"nctId":"NCT07450976","phase":"PHASE2","title":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Biliary Tract Cancer","enrollment":151},{"nctId":"NCT07466303","phase":"PHASE2","title":"Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-25","conditions":"Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer","enrollment":84},{"nctId":"NCT05238792","phase":"PHASE1","title":"Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2021-11-17","conditions":"Solid Tumor","enrollment":36},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT07422480","phase":"PHASE3","title":"A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-04-01","conditions":"Myelodysplastic Syndrome, Anemia","enrollment":300},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT04376762","phase":"PHASE4","title":"Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2021-10-26","conditions":"Pediatric HD, Bleeding","enrollment":31},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT04170946","phase":"PHASE1","title":"Talazoparib and Thoracic RT for ES-SCLC","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-10-05","conditions":"Lung Cancer, Small-Cell Lung Cancer","enrollment":24},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT03070327","phase":"PHASE1","title":"BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-27","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT06321484","phase":"PHASE1","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-09","conditions":"Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer","enrollment":18},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT04328662","phase":"","title":"A Study of Ninlaro in Real World Clinical Practice in China","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-05-18","conditions":"Multiple Myeloma, Neoplasms, Plasma Cell","enrollment":482},{"nctId":"NCT07276880","phase":"PHASE2","title":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-03","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT04988074","phase":"PHASE2","title":"Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-12-13","conditions":"HPV-Related Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT07444541","phase":"PHASE1, PHASE2","title":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anova Innovation Limited","startDate":"2026-03","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT02031250","phase":"PHASE2","title":"Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":106},{"nctId":"NCT07440784","phase":"NA","title":"Impact Of Intermittent And Water-Only Fasting On Gene Expression And Tumor Markers In Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2022-08-01","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT04469530","phase":"PHASE2","title":"Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-09-16","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT07416682","phase":"EARLY_PHASE1","title":"CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2026-01-31","conditions":"High-risk Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT07430917","phase":"PHASE2","title":"Safety and Efficacy of J147 in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Abrexa Pharmaceuticals, Inc.","startDate":"2026-03-20","conditions":"Acute Ischemic Stroke","enrollment":196},{"nctId":"NCT06791434","phase":"PHASE4","title":"Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment","status":"COMPLETED","sponsor":"Dr. Vishwanath Karad MIT World Peace University","startDate":"2024-08-30","conditions":"Low Back Pain","enrollment":156},{"nctId":"NCT07428148","phase":"PHASE1, PHASE2","title":"Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-05","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT07177079","phase":"PHASE1","title":"High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Kittika Poonsombudlert","startDate":"2026-05-31","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT04851015","phase":"PHASE3","title":"Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2025-11-28","conditions":"Pneumocystis, Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection","enrollment":416},{"nctId":"NCT03729518","phase":"NA","title":"TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2018-10-11","conditions":"Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus","enrollment":150},{"nctId":"NCT06666348","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK","status":"RECRUITING","sponsor":"St. Justine's Hospital","startDate":"2026-01-12","conditions":"Pediatric Low-grade Glioma","enrollment":50},{"nctId":"NCT06513065","phase":"PHASE3","title":"Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2024-12-04","conditions":"Pseudomyxoma Peritonei","enrollment":176},{"nctId":"NCT00352534","phase":"PHASE3","title":"Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2006-11-06","conditions":"Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor","enrollment":808},{"nctId":"NCT07418866","phase":"PHASE2","title":"FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":70},{"nctId":"NCT07408609","phase":"PHASE2","title":"Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-26","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":114},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT07397442","phase":"PHASE2","title":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-03-01","conditions":"Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":19},{"nctId":"NCT04994717","phase":"PHASE3","title":"Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Amgen","startDate":"2021-11-02","conditions":"Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)","enrollment":304},{"nctId":"NCT04862650","phase":"PHASE2","title":"Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcelo Bonomi","startDate":"2021-11-30","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT02162849","phase":"PHASE4","title":"Reward Sensitivity and Pharmacotherapy for Smoking Cessation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-12-14","conditions":"Tobacco Use Cessation","enrollment":204},{"nctId":"NCT06610734","phase":"PHASE2","title":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-12-23","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":202},{"nctId":"NCT04419649","phase":"PHASE2","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Takeda","startDate":"2020-08-19","conditions":"Myelodysplastic Syndromes, Cytopenia","enrollment":160},{"nctId":"NCT05962242","phase":"PHASE2","title":"HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-06-28","conditions":"Squamous Cell Carcinoma of the Oropharynx","enrollment":90},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT07172204","phase":"PHASE2","title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-16","conditions":"Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60","enrollment":25},{"nctId":"NCT04833816","phase":"PHASE3","title":"Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2022-08-05","conditions":"Traumatic Injury","enrollment":140},{"nctId":"NCT05691010","phase":"EARLY_PHASE1","title":"A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-01-10","conditions":"Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma","enrollment":28},{"nctId":"NCT05847569","phase":"PHASE2","title":"Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-04","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":62},{"nctId":"NCT07383818","phase":"PHASE2","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-02-01","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":111},{"nctId":"NCT06840977","phase":"","title":"COLON ERDERLY LOW DOSE","status":"NOT_YET_RECRUITING","sponsor":"Matteo Clavarezza","startDate":"2026-02-01","conditions":"Colon Adenocarcinoma","enrollment":51},{"nctId":"NCT06866964","phase":"PHASE2","title":"A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-08-28","conditions":"Germ Cell Tumor, Testicular Cancer","enrollment":35},{"nctId":"NCT03323944","phase":"PHASE1","title":"CAR T Cell Immunotherapy for Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2017-09-15","conditions":"Pancreatic Cancer, Cancer of the Pancreas","enrollment":54},{"nctId":"NCT06318871","phase":"EARLY_PHASE1","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-28","conditions":"Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma","enrollment":10},{"nctId":"NCT04614168","phase":"NA","title":"Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2021-07-26","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia, Hypoglycemia","enrollment":24},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT06910943","phase":"PHASE2, PHASE3","title":"Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support","status":"RECRUITING","sponsor":"Protara Therapeutics","startDate":"2025-12-10","conditions":"Choline Deficiency, Liver Injury","enrollment":129},{"nctId":"NCT06239272","phase":"PHASE1, PHASE2","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-27","conditions":"Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma","enrollment":139},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT05978193","phase":"PHASE2","title":"Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT02961101","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies","status":"RECRUITING","sponsor":"Han weidong","startDate":"2016-05","conditions":"Malignancies Multiple","enrollment":250},{"nctId":"NCT07353294","phase":"PHASE1","title":"Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Bladder Urothelial Carcinoma, Lymph Node Metastasis","enrollment":12},{"nctId":"NCT02969837","phase":"PHASE2","title":"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-07-10","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT07347951","phase":"PHASE2","title":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-12-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":614,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["•Thalidomide •Celecoxib •Etoposide •Cyclophosphamide"],"phase":"phase_3","status":"active","brandName":"Low dose chemotherapy","genericName":"Low dose chemotherapy","companyName":"All India Institute of Medical Sciences","companyId":"all-india-institute-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low dose chemotherapy uses reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing systemic toxicity. Used for Various solid tumors and hematologic malignancies (specific indications dependent on Phase 3 trial design).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}